Search

everythinglearnresearchcommunity

for

Search:↓

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

Reduced SIRT1 in hair cells may cause alopecia areata by triggering immune responses.

Certain human skin cells marked by CD44 and ALDH are rich in stem cells capable of long-term skin renewal.

Plasmacytoid dendritic cells are a key factor in causing hair loss in alopecia areata and could help differentiate it from other hair loss conditions.

Deleting the CD271 gene in mouse skin cells leads to disorganized skin and increased hair growth, suggesting CD271 is important for skin health.

A man developed a skin cancer called folliculotropic mycosis fungoides after a kidney transplant.

Engineered nanovesicles from hair follicle stem cells enable scarless healing of infected wounds.

CMV infection increases the risk of GvHD after bone marrow transplants.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

Abnormal T-cells from thymomas cause non-motor symptoms in some myasthenia gravis patients.

Moderate immune responses help hair growth, while excessive responses slow it down.

Tumor proteins can both promote and suppress cancer, depending on the situation.

Anti-EGFR therapy can cause skin issues, but FGF7 treatment might help.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Zinc may help treat alopecia areata by boosting certain immune cells.

Immune cells are essential for skin regeneration using biomaterial scaffolds.

ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.

Atopic dermatitis may trigger alopecia areata, and early treatment can help prevent severe cases.

Mechlorethamine treatment regrew hair in mice by killing immune cells causing hair loss without harming hair follicles.

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

M-CSF-stimulated myeloid cells can turn into skin cells and help heal wounds and regrow hair.

Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.

AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.

Nonimmunosuppressive cyclosporines might treat skin diseases by affecting cell growth.

Telocytes might help with skin repair and regeneration.

Personalized treatment considering atopic status and cytokine profiles may help in managing pediatric alopecia areata.

A new skin disease in four Labrador retrievers responded well to immunosuppressive treatment.

The humanized AA mouse model is better for testing new alopecia areata treatments.

Noncoding dsRNA boosts hair growth by activating TLR3 and increasing retinoic acid.